Development asset linked to Philogen in public FDA and regional records.
pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen
Philogen S.p.A.
Philogen drug portfolio — 29 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Loc. Bellaria, 35, Sovicille, SIENA 53018, IT HQ
1996 Founded
180 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
- Founded
- 1996
- Employees
- 180
- Programs
- 18
- Drugs
- 29
- Patents
- 0
Philogen pipeline
Portfolio lens on 29 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Philogen drug portfolio — 29 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Philogen in public FDA and regional records.
-
Development asset linked to Philogen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to Philogen in public FDA and regional records.
-
Development asset linked to Philogen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Philogen in public FDA and regional records.
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Philogen's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
enoxaparin sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Philogen in public FDA and regional records.
-
Development asset linked to Philogen in public FDA and regional records.
-
Development asset linked to Philogen in public FDA and regional records.
-
Development asset linked to Philogen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Philogen in public FDA and regional records.
-
Development asset linked to Philogen in public FDA and regional records.
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Philogen in public FDA and regional records.
-
Development asset linked to Philogen in public FDA and regional records.
-
Development asset linked to Philogen in public FDA and regional records.
-
ruxolitinib
Dermatologicals (D11)US regulatory status: approved. Mechanism: Tyrosine-protein kinase JAK2 inhibitor.
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
Development asset linked to Philogen in public FDA and regional records.
-
Development asset linked to Philogen in public FDA and regional records.
-
Development asset linked to Philogen in public FDA and regional records.
-
temozolomide
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Philogen in public FDA and regional records.
-
Development asset linked to Philogen in public FDA and regional records.